This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens Boots Alliance (WBA) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $9.01, indicating a -0.55% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $8.84, representing a +1.14% change from its previous close.
Why the Market Dipped But Walgreens Boots Alliance (WBA) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $8.77, denoting a +0.34% change from the preceding trading day.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon are part of the Zacks Industry Outlook article.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) reachead $8.74 at the closing of the latest trading day, reflecting a +1.04% change compared to its last close.
3 Stocks to Avoid From The Volatile Retail Pharmacy Industry
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS, WBA and HLF are likely to be affected by reimbursement challenges that are hurting the overall health of the industry.
CVS Stock Tanks 27.5% Year to Date: Time to Buy the Dip?
by Urmimala Biswas
While CVS Health has been grappling with pharmacy reimbursement pressure, a turnaround might be in the cards, given its several strategic initiatives.
Walgreens Boots Alliance (WBA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $10.38, marking a +0.78% move from the previous day.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Walgreens Boots Alliance (WBA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $10.92 in the latest trading session, marking a +0.92% move from the prior day.
Interactive Brokers and Walgreens Boots Alliance have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Interactive Brokers and Walgreens Boots Alliance are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Walgreens Boots Alliance (WBA)
by Derek Lewis
WBA has been a classic example of 'it can always go lower', with shares unable to find any traction over recent years.
The Zacks Analyst Blog CVS Health, Walgreens and Herbalife
by Zacks Equity Research
CVS Health, Walgreens and Herbalife are included in this Analyst Blog.
What is the Right Approach for CVS Health (CVS) Post Q2 Results?
by Urmimala Biswas
The near-term challenges for CVS Health (CVS) are no doubt worrisome. Yet, the company remains focused on its strategic moves, utilizing integrated healthcare models and technological advancements.
Company News for Aug 6, 2024
by Zacks Equity Research
Companies In The Article Are:CG, WBA, K and TSN
Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
CVS Health (CVS) is grappling with a sudden increase in Medicare Advantage members' utilization trend. The Medicaid business, too, is expected to have experienced medical cost pressure in the second quarter.
CVS Health (CVS) Falls 24% in 3 Months: Should You Buy the Dip?
by Urmimala Biswas
While CVS Health (CVS) has been grappling with the pharmacy reimbursement pressure, a turnaround might be in the cards given its several strategic initiatives.
Super Micro Computer and Walgreens Boots Alliance have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Super Micro Computer and Walgreens Boots Alliance are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Walgreens Boots Alliance (WBA)
by Derek Lewis
Margin pressures and lowered guidance paint a challenging picture for the company's shares in the near term.
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
by Zacks Equity Research
An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.
Nike and Walgreens Boot Alliance are part of Zacks Earnings Preview
by Zacks Equity Research
Nike and Walgreens Boot Alliance are highlights of Zacks Earnings Preview article.
Q2 Earnings Growth Forecasted to Hit Two-Year High
by Sheraz Mian
Q2's expected quarterly earnings growth pace of +8.3% reflects the strongest growth since back in Q1 of 2022. Tech is expected to do some heavy lifting again, with earnings expected to be up +15.5% on +9.5% higher revenues.
Top and Flop ETFs of the First Half
by Sweta Killa
We have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.